Fig. 1: The bortezomib sensitivity of HNSCC is associated with the expression level of ΔNp63α.
From: ΔNp63α promotes Bortezomib resistance via the CYGB–ROS axis in head and neck squamous cell carcinoma
A UMSCC-17B, UMSCC-11, UMSCC-17A, and HN31 cells were treated with increasing concentrations of bortezomib (0.01–10000 nM) for 24 h, viable cells were quantified using the CCK-8 assay. Each data point represents the means ± SD of three separate experiments. B. Western blot was performed to analyze ΔNp63α proteins levels of UMSCC-17B, UMSCC-11, UMSCC-17A, and HN31 cells. C. Four cells were observed for ΔNp63α by immunostaining with antibody (green). Nuclei are counterstained with DAPI (blue). Scale bar: 20 μm. D. After “step-wise” inducing drug-resistance cell culture, 17B-R-10nM drug-resistant cell line that can proliferate in culture medium containing 10 nM bortezomib was obtained. IC50 of 17B-R-5nM and 17B-R-10nM were calculated using, CCK-8 assay. E. UMSCC-17B, 17B-R-5nM, and 17B-R-10nM were observed for ΔNp63α by immunostaining with antibody (green) Scale bar: 20 μm. F. Altered expressions of ΔNp63α were evaluated by western blot analysis in UMSCC-17B, 17B-R-5nM, and 17B-R-10nM.
